Jennifer Arrondeau

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet et al. · Clinical Cancer Research · 2018 · 361 citations

Life Sciences, Immunology, Oncology +17

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Diane Damotte, Sarah Warren, Jennifer Arrondeau et al. · Journal of Translational Medicine · 2019 · 150 citations · Full text

Medicine, Immunology, Oncology +17

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux‐Leprieur et al. · Cancers · 2020 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib exposure decreases over time in patients with hepatocellular carcinoma

Jennifer Arrondeau, Olivier Mir, Pascaline Boudou‐Rouquette et al. · Investigational New Drugs · 2011 · 104 citations

Medicine, Oncology, Pharmacotherapy +12